IBL will develop biomarker panels for use with Grifols' random-access, single-molecule counting platform, and the firms will collaborate on testing workflows.

The firm recently announced agreements with Labcorp and Quest Diagnostics to provide its devices for self-collection of vaginal swab specimens.

Last week, readers were most interested in a story about the overturning by a federal court of the FDA's LDT rule.

While AI-based tools have become widely used for documentation and clerical tasks, developers and healthcare experts see a greater future role in clinical care.

The ruling makes clear that the FDA lacks the legal authority to regulate LDTs, and observers suggest it could also call into question its authority in other areas.

The firm said that investors provided better-than-expected backing as the company anticipates growing use of its digital pathology platform in 2025.

The aggregate repurchase authorization program now totals $200 million, which the firm will fund with cash and cash equivalents.

The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.

Laboratory Corporation of America said this week it has launched its pTau-217/Beta Amyloid 42 Ratio blood test for aiding the diagnosis of Alzheimer's disease. The immunoassay measures the ratio of ...

Agilent Technologies said that Heidi Kunz is resigning from the company's board of directors as well as the firm's compensation committee and nominating and corporate governance committee, effective ...